211 related articles for article (PubMed ID: 19127263)
1. Promoter CpG methylation in cancer cells contributes to the regulation of MUC4.
Yamada N; Nishida Y; Tsutsumida H; Goto M; Higashi M; Nomoto M; Yonezawa S
Br J Cancer; 2009 Jan; 100(2):344-51. PubMed ID: 19127263
[TBL] [Abstract][Full Text] [Related]
2. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases.
Vincent A; Ducourouble MP; Van Seuningen I
FASEB J; 2008 Aug; 22(8):3035-45. PubMed ID: 18492726
[TBL] [Abstract][Full Text] [Related]
4. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells.
Meng CF; Zhu XJ; Peng G; Dai DQ
Oncol Rep; 2009 Nov; 22(5):1221-7. PubMed ID: 19787243
[TBL] [Abstract][Full Text] [Related]
5. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Ikehata M; Ueda K; Iwakawa S
Biol Pharm Bull; 2012; 35(3):301-7. PubMed ID: 22382314
[TBL] [Abstract][Full Text] [Related]
6. Unique methylation pattern of oncostatin m receptor gene in cancers of colorectum and other digestive organs.
Deng G; Kakar S; Okudiara K; Choi E; Sleisenger MH; Kim YS
Clin Cancer Res; 2009 Mar; 15(5):1519-26. PubMed ID: 19223499
[TBL] [Abstract][Full Text] [Related]
7. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
[TBL] [Abstract][Full Text] [Related]
8. MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine.
David GL; Yegnasubramanian S; Kumar A; Marchi VL; De Marzo AM; Lin X; Nelson WG
Cancer Biol Ther; 2004 Jun; 3(6):540-8. PubMed ID: 15034303
[TBL] [Abstract][Full Text] [Related]
9. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
[TBL] [Abstract][Full Text] [Related]
10. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells.
Wischnewski F; Pantel K; Schwarzenbach H
Mol Cancer Res; 2006 May; 4(5):339-49. PubMed ID: 16687489
[TBL] [Abstract][Full Text] [Related]
11. Histone H3 (lys-9) deacetylation is associated with transcriptional silencing of E-cadherin in colorectal cancer cell lines.
Liu Y; Hong Y; Zhao Y; Ismail TM; Wong Y; Eu KW
Cancer Invest; 2008 Jul; 26(6):575-82. PubMed ID: 18584348
[TBL] [Abstract][Full Text] [Related]
12. Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.
Magdinier F; Wolffe AP
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):4990-5. PubMed ID: 11309512
[TBL] [Abstract][Full Text] [Related]
13. Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites.
Chen C; Yang MC; Yang TP
J Biol Chem; 2001 Jan; 276(1):320-8. PubMed ID: 11013250
[TBL] [Abstract][Full Text] [Related]
14. Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Al-Nakhle H; Smith L; Bell SM; Burns PA; Cummings M; Hanby AM; Lane S; Parker MD; Hughes TA; Speirs V
Int J Oncol; 2013 Dec; 43(6):2039-45. PubMed ID: 24068253
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypomethylation contributes to the expression of MUC3A in cancer cells.
Kitamoto S; Yamada N; Yokoyama S; Houjou I; Higashi M; Yonezawa S
Biochem Biophys Res Commun; 2010 Jun; 397(2):333-9. PubMed ID: 20510874
[TBL] [Abstract][Full Text] [Related]
16. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure.
Woodfield GW; Hitchler MJ; Chen Y; Domann FE; Weigel RJ
Clin Cancer Res; 2009 Jun; 15(11):3672-9. PubMed ID: 19458056
[TBL] [Abstract][Full Text] [Related]
17. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.
Yamada N; Hamada T; Goto M; Tsutsumida H; Higashi M; Nomoto M; Yonezawa S
Int J Cancer; 2006 Oct; 119(8):1850-7. PubMed ID: 16721789
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic silencing of maspin expression occurs early in the conversion of keratocytes to fibroblasts.
Horswill MA; Narayan M; Warejcka DJ; Cirillo LA; Twining SS
Exp Eye Res; 2008 Apr; 86(4):586-600. PubMed ID: 18291368
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy.
Algamas-Dimantov A; Yehuda-Shnaidman E; Peri I; Schwartz B
Cell Oncol (Dordr); 2013 Apr; 36(2):155-67. PubMed ID: 23307400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
